HOUSTON and MELBOURNE, Australia, Jan. 22, 2018 /PRNewswire/ — Vyripharm Biopharmaceutical (VB)Â announces a collaboration with WardMM, to establish clinical trialÂ partnership/Joint Venture (JV) forÂ the use of medical botanicals in patients. TheÂ JVÂ representsÂ aÂ globalÂ first in a collaboration to produce comprehensive precision pharmaceutical grade medicine, derived from medical botanicals. TheÂ JVÂ is positionedÂ toÂ be first in humans and set standardization for future clinical trial studies withÂ medical cannabis derivatives.Â The focus of precision medicine will be our platform from agriculture to treatment for safer alternatives and higher efficacy for patients.Â Vyripharm maintains research partnerships with institutions throughout the Texas Medical Center focused on the integration and effects of medical botanicals with traditional standard of care in treatments for cancer, post-traumatic stress disorder, substance abuse, contact sport injuries, pain management and neurological disorders. WardMM maintains relationships with research institutions both in the USA and Australia and licensed medicinal cannabis companies in Australia.
This JV aims to determine
... read more at: http://markets.businessinsider.com/news/stocks/Vyripharm-and-WardMM-announce-clinical-trial-partnership-for-the-integration-of-traditional-standard-pharmaceuticals-with-medical-botanicals-and-the-application-of-big-data-in-precision-medicine-1013604713